We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00118209
Recruitment Status : Completed
First Posted : July 11, 2005
Results First Posted : April 17, 2020
Last Update Posted : November 17, 2021
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

Tracking Information
First Submitted Date  ICMJE July 8, 2005
First Posted Date  ICMJE July 11, 2005
Results First Submitted Date  ICMJE April 6, 2020
Results First Posted Date  ICMJE April 17, 2020
Last Update Posted Date November 17, 2021
Actual Study Start Date  ICMJE May 2005
Actual Primary Completion Date October 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 6, 2020)
Progression-Free Survival Rate at 2 and 5 Years [ Time Frame: Up to 5 years post-registration ]
Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>
  • ≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>
  • Appearance of any new lesion during or after completion of therapy.>
  • PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>
The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below.
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 6, 2020)
  • Response Rate [ Time Frame: Up to 5 years post-registration ]
    The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response)
  • Overall Survival Rate at 2 and 5 Years [ Time Frame: Up to 5 years post-registration ]
    Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: April 6, 2020)
Whether the Gene Expression Signatures That Were Previously Associated With Survival Following CHOP Therapy Are Associated With Survival in Either of the Treatment Arms of the Prospective Trial [ Time Frame: Up to 5 years post-registration ]
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Official Title  ICMJE Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Brief Summary

This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

Detailed Description

PRIMARY OBJECTIVES:

I. To compare the event-free survival of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (R-CHOP) versus dose-adjusted (DA-) etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, and rituximab (EPOCH-R) chemotherapy in untreated cluster of differentiation (CD)20 positive (+) diffuse large B-cell lymphomas.

II. To develop a molecular predictor of outcome of R-CHOP and DA-EPOCH-R chemotherapy using molecular profiling.

SECONDARY OBJECTIVES:

I. To compare the response rates, overall survival and toxicity of R-CHOP versus DA-EPOCH-R.

II. To define the pharmacogenomics of untreated diffuse large B-cell lymphoma (DLBCL) and correlate clinical parameters (toxicity, response, survival outcomes and laboratory results) with molecular profiling.

III. To assess the use of molecular profiling for pathological diagnosis. IV. To identify new therapeutic targets using molecular profiling. V. To perform a comprehensive analysis of somatic alterations to the tumor genome and to understand which genomic alterations are somatically acquired by the tumor and which are encoded in the germ line of the patient.

VI. To identify biomarkers of response to chemotherapy by fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging that are predictive of histopathologic remissions and survival in patients with stage I (mediastinal), II, III, or IV untreated DLBCL.

VII. To evaluate the use of semiquantitative measurements of FDG uptake in defining FDG-PET/CT based biomarkers of response to chemotherapy in patients with DLBCL.

VIII. To determine whether FDG-PET/CT measurements of tumor response after the second cycle of chemotherapy can predict clinical response.

IX. To establish a standardized protocol for FDG-PET/CT image acquisition. X. To determine additional FDG-PET/CT parameters (e.g., the ratio of tumor maximum standard uptake value [SUVmax] to liver SUVmean; SUVs corrected for body surface area and lean body mass; nuclear medicine physician's assessment) and evaluate their utility in refining FDG-PET/CT based biomarkers of response to therapy.

XI. To evaluate inter-institutional reproducibility of FDG-PET/CT measurements for this indication.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Large B Cell Lymphoma
Intervention  ICMJE
  • Biological: rituximab
    IV
  • Drug: cyclophosphamide
    IV
  • Drug: doxorubicin
    IV or CIVI
  • Drug: vincristine
    IV or CIVI
  • Drug: prednisone
    oral
  • Drug: etoposide
    CIVI
  • Drug: filgrastim
    IV
  • Drug: pegfilgrastim
    IV
Study Arms  ICMJE
  • Active Comparator: Arm A - R-CHOP

    Patients receive the following treatment:

    • Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy
    • Cyclophosphamide 750 mg/m^2 IV on Day 1
    • Doxorubicin 50 mg/m^2 IV on Day 1
    • Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1
    • Prednisone 40 mg/m^2/day PO on Days 1-5
    • filgrastim or pegfilgrastim as defined in the protocol

    Required ancillary medications is administered during all cycles as defined in the protocol.

    Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.

    Interventions:
    • Biological: rituximab
    • Drug: cyclophosphamide
    • Drug: doxorubicin
    • Drug: vincristine
    • Drug: prednisone
    • Drug: filgrastim
    • Drug: pegfilgrastim
  • Experimental: Arm B - DA-EPOCH-R

    Patients receive the following treatment:

    Cycle 1 Doses:

    • Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy
    • Doxorubicin 10 mg/m^2/day CIVI on Days 1-4
    • Etoposide 50 mg/m^2/day CIVI on Days 1-4
    • Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)
    • Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)
    • Prednisone 60 mg/m^2 PO BID on Days 1-5
    • Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.

    Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.

    Required ancillary medications are administered during all cycles as defined in the protocol.

    Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.

    Interventions:
    • Biological: rituximab
    • Drug: cyclophosphamide
    • Drug: doxorubicin
    • Drug: vincristine
    • Drug: prednisone
    • Drug: etoposide
    • Drug: filgrastim
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 6, 2020)
524
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE November 15, 2021
Actual Primary Completion Date October 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  1. Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease.

    • Stage I primary mediastinal (thymic) DLBCL is also eligible.
    • Patients with an underlying low-grade lymphoma, such as a transformed lymphoma or low-grade lymphoma in the bone marrow, are not eligible.
    • Diagnosis should be based on an adequate tissue sample, including open biopsy or core needle biopsy.
    • Needle aspiration for primary diagnosis is unacceptable.
    • Patients must have one of the following WHO classification subtypes:

      • Diffuse large B-cell lymphoma (includes morphological variants: centroblastic, immunoblastic, T-cell/histiocyte rich, and anaplastic)
      • Mediastinal (thymic) large B-cell lymphoma
      • Intravascular large B-cell lymphoma
    • Note: Failure to submit a pathology block within 60 days of patient registration will be considered a major protocol violation.

      • Fresh (frozen) tumor biopsy must be available or attempted. A frozen tumor biopsy equivalent to a minimum of four at least 16 gauge needle cores is an important component of this study.
      • Patients without adequate frozen material should have a biopsy performed to obtain material.
      • If a biopsy is performed and does not yield adequate material, the patient is still eligible for the study. If a biopsy cannot be done safely, the patient may still be eligible for the study if permission is granted.
    • Note: This study does not allow concurrent radiation unless a patient has a documented CNS treatment failure with no systemic failure.
  2. No prior cytotoxic chemotherapy or rituximab. Patients may be entered if they have received prior limited field radiation therapy or a short course of glucocorticoids (< 10 days) for an urgent local disease complication at diagnosis (e.g., cord compression, SVC syndrome). Patients who have received chemotherapy for prior malignancies are not eligible.
  3. Age ≥ 18 years
  4. ECOG Performance Status 0-2
  5. No active ischemic heart disease or congestive heart failure. If there is suspicion of cardiac disease, a cardiac ejection fraction must show LVEF > 45%, but the study is not required
  6. No known lymphomatous involvement of the CNS. A lumbar puncture prior to study is not required in the absence of neurological symptoms
  7. No known HIV disease. Patients with a history of intravenous drug abuse or any other behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus. Patients who test positive or who are known to be infected are not eligible.
  8. Non pregnant and non-nursing. Treatment would expose an unborn child to significant risks. Women and men of reproductive potential should agree to use an effective form of contraception.
  9. Patients with active medical processes (e.g., uncontrolled bacterial or viral infection, bleeding) not related to their lymphoma should be excluded.
  10. Required Initial Laboratory Values (unless non-Hodgkin lymphoma):

    • ANC ≥ 1000/μL
    • Platelets ≥ 100,000/μL
    • Creatinine≤ 1.5 mg/dL or creatinine clearance ≥ 50 cc/min
    • Total Bilirubin ≤ 2 mg/dL (unless a history of Gilbert's Disease)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00118209
Other Study ID Numbers  ICMJE CALGB-50303
CDR0000433265 ( Other Identifier: NCI Physician Data Query )
NCI-2009-00480 ( Registry Identifier: NCI Clinical Trial Reporting Program )
U10CA031946 ( U.S. NIH Grant/Contract )
U10CA180821 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Alliance for Clinical Trials in Oncology
Original Responsible Party Not Provided
Current Study Sponsor  ICMJE Alliance for Clinical Trials in Oncology
Original Study Sponsor  ICMJE Cancer and Leukemia Group B
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Wyndham H. Wilson, MD, PhD National Cancer Institute (NCI)
Study Chair: Andrew D. Zelenetz, MD, PhD Memorial Sloan Kettering Cancer Center
PRS Account Alliance for Clinical Trials in Oncology
Verification Date November 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP